News | July 18, 2022
China Pharma submits plan of compliance to NYSE American
The company was directed to submit a plan of compliance by July 15, 2022
The company was directed to submit a plan of compliance by July 15, 2022
She joins Enveda from Gilead Sciences
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
MINYM can be safely used by patients above 9 years of age.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Subscribe To Our Newsletter & Stay Updated
